SCHEMBL204623

SCHEMBL204623

CCN(Cc1ccccc1)C(=O)CCC(=O)NC1CCC(Cc2cccc(C)c2)(N(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRL1 P41146 2/20 0.41
SSTR1 P30872 1/20 0.41
SSTR4 P31391 1/20 0.41
PTGES O14684 2/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207235 0.91 KMT2A (0.47) KMT2AMEN1SMN1; SMN2OPRM1OPRL1
SCHEMBL207303 0.90 SIGMAR1 (0.46) KMT2AMEN1SMN1; SMN2OPRM1OPRL1
SCHEMBL206157 0.90 NPC1 (0.46) KMT2AMEN1OPRM1OPRL1SSTR1
SCHEMBL4075132 0.84 SSTR4 (0.43) KMT2AMEN1OPRM1OPRL1SSTR1
SCHEMBL4052851 0.84 KMT2A (0.48) KMT2AMEN1OPRM1OPRL1SSTR1
SCHEMBL206665 0.83 SSTR4 (0.45) KMT2AMEN1OPRM1OPRL1SSTR1
SCHEMBL206736 0.82 HPGD (0.48) KMT2AMEN1SMN1; SMN2OPRM1OPRL1
SCHEMBL4073100 0.81 SSTR1 (0.39) KMT2AMEN1OPRM1OPRL1SSTR1
SCHEMBL5157976 0.81 SSTR4 (0.45) KMT2AMEN1SMN1; SMN2OPRM1OPRL1
SCHEMBL207003 0.81 KMT2A (0.39) KMT2AMEN1OPRM1OPRL1SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD KMT2A 3604/4885MEN1 713/4885SMN1; SMN2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.